An Exploratory Phase II Study of PHA-739358 in Patients With Multiple Myeloma Harbouring the t(4;14) Translocation With or Without FGFR3 Expression.
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2014
At a glance
- Drugs Danusertib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Nerviano Medical Sciences
- 07 Jun 2017 Biomarkers information updated
- 29 Sep 2009 Actual end date (Sep 2010) and actual number of patients (7) added as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.